TaiMed Biologics Inc. (TPEX:4147)
Taiwan · Delayed Price · Currency is TWD 64.90
+2.20 (3.51%)
Sep 8, 2026, 12:50 PM CST
TaiMed Biologics Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 17,130 | 16,720 | 23,485 | 20,746 | 17,843 | 17,813 | |
Market Cap Growth | -22.30% | -28.80% | 13.20% | 16.27% | 0.17% | -16.02% |
Enterprise Value | 16,003 | 15,456 | 21,842 | 20,859 | 17,860 | 17,487 |
Last Close Price | 62.70 | 61.20 | 86.00 | 80.83 | 69.69 | 69.59 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 46.48 | 46.48 | 282.76 | 41.73 | 182.22 |
PS Ratio | 27.65 | 27.35 | 38.49 | 42.19 | 31.69 | 43.09 |
PB Ratio | 4.66 | 4.33 | 5.84 | 8.09 | 6.57 | 6.06 |
P/TBV Ratio | 5.22 | 4.89 | 6.74 | 10.69 | 8.96 | 8.40 |
P/FCF Ratio | 158.60 | 99.24 | - | - | - | - |
P/OCF Ratio | 110.43 | 87.47 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 25.83 | 25.28 | 35.80 | 42.42 | 31.72 | 42.30 |
EV/FCF Ratio | 148.17 | 91.74 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.13 | 0.13 | 0.29 | 0.28 | 0.19 |
Debt / FCF Ratio | 4.43 | 2.93 | - | - | - | - |
Net Debt / Equity Ratio | -0.31 | -0.33 | -0.28 | 0.04 | 0.05 | -0.13 |
Net Debt / EBITDA Ratio | 28.81 | 27.42 | 10.81 | -5.89 | -2.92 | 1.16 |
Net Debt / FCF Ratio | -10.43 | -7.57 | 2.91 | -3.29 | -0.20 | 1.77 |
Asset Turnover | 0.13 | 0.13 | 0.14 | 0.12 | 0.13 | 0.08 |
Inventory Turnover | 0.24 | 0.24 | 0.28 | 0.20 | 0.27 | 0.27 |
Quick Ratio | 8.63 | 7.48 | 13.26 | 2.31 | 2.32 | 5.12 |
Current Ratio | 15.48 | 13.11 | 25.18 | 5.96 | 6.56 | 10.37 |
Return on Equity (ROE) | -3.66% | -4.26% | -6.13% | -7.38% | -9.52% | -14.82% |
Return on Assets (ROA) | -2.52% | -2.48% | -3.55% | -2.60% | -2.75% | -6.20% |
Return on Capital Employed (ROCE) | -4.40% | -4.30% | -5.20% | -4.70% | -5.10% | -11.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.81% | -1.00% | -0.86% | -0.94% | -1.51% | -2.64% |
FCF Yield | 0.63% | 1.01% | -1.65% | -0.15% | -3.41% | -1.24% |
Buyback Yield / Dilution | 0.22% | -1.85% | -6.08% | -0.18% | -0.04% | -0.03% |